$2.44
0.44% today
Nasdaq, Feb 28, 05:17 pm CET
ISIN
US5894921072
Symbol
MREO
Sector
Industry

Mereo BioPharma Group plc Sponsored ADR Stock price

$2.45
-0.47 16.10% 1M
-2.35 48.96% 6M
-1.05 30.00% YTD
-1.42 36.69% 1Y
+1.21 97.58% 3Y
+0.67 37.64% 5Y
-4.05 62.31% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.00 0.00%
ISIN
US5894921072
Symbol
MREO
Sector
Industry

Key metrics

Market capitalization $379.10m
Enterprise Value $305.26m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 5.23
Cash position $80.52m
P/E forward negative
P/S forward 20.92
EV/Sales forward 16.84
Short interest 3.98%

Is Mereo BioPharma Group plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Mereo BioPharma Group plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast:

Buy
100%

Financial data from Mereo BioPharma Group plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.28 0.28
-
-
-0.28 -0.28
-
-
- Selling and Administrative Expenses 5.70 5.70
-
-
- Research and Development Expense 3.20 3.20
-
-
-9.18 -9.18
-
-
- Depreciation and Amortization 0.28 0.28
-
-
EBIT (Operating Income) EBIT -9.47 -9.47
-
-
Net Profit -15 -15
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Mereo BioPharma Group plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mereo BioPharma Group plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
about 2 months ago
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025
Neutral
GlobeNewsWire
about 2 months ago
LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 8:15am PT / 04:15pm GMT.
Positive
Seeking Alpha
3 months ago
Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from the phase 2/3 ORBIT study indicates a significant reduction in fracture rates, bolstering confidence in ongoing phase 3 trials. Financially stable with $87.4 million in cash, Mereo aims to secure a...
More Mereo BioPharma Group plc Sponsored ADR News

Company Profile

Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Denise Scots-Knight
Employees 33
Founded 2015
Website www.mereobiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today